Novo Nordisk Rolls Out Ozempic Across India At ₹2,200 A Week

2025-12-12 02:12:30

(MENAFN- The Arabian Post)

Danish pharmaceutical company Novo Nordisk has launched its blockbuster diabetes and weight-related therapy Ozempic in India, making the semaglutide-based injectable available across the country with a starting cost of about ₹2,200 per week for the lowest 0.25 mg dose. The move positions Ozempic as a key element in the fast-evolving metabolic health market, where type 2 diabetes and obesity rates are among the highest globally.

Available in pre-filled pens with 0.25 mg, 0.5 mg and 1 mg strengths, the therapy has been approved in India as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes. Novo Nordisk has set the monthly cost for the 0.25 mg dose at approximately ₹8,800, with incremental pricing for the higher strengths. The company says Ozempic delivers benefits beyond glycaemic control, including cardiovascular and kidney risk reduction, and supports weight management through appetite suppression.

India's diabetes burden is among the world's largest, with more than 100 million adults affected, according to World Health Organization estimates. Additionally, hundreds of millions live with overweight or obesity, factors that increase the risk of metabolic complications. The introduction of a globally validated therapy such as Ozempic provides clinicians with another option in managing these interconnected health challenges.

Industry analysts note that the launch comes as the country becomes a major battleground for GLP-1 receptor agonist drugs - a class that includes semaglutide and competitors such as Eli Lilly's tirzepatide, marketed locally as Mounjaro. These therapies mimic gut hormones to regulate blood glucose and appetite, and have become focal points in efforts to curb both diabetes and excess weight.

See also Amazon eyes deeper India expansion with $35 billion pledge

Novo Nordisk's roll-out follows the entry of Wegovy, its higher-dose semaglutide formulation specifically approved for chronic weight management, which debuted in India earlier in the year. Wegovy's pricing adjustments have sparked a noticeable uptick in uptake, highlighting how cost influences adoption of these premium therapies. Ozempic's pricing at a relatively lower weekly rate aims to broaden its accessibility, though some clinicians stress that affordability will remain a concern for patients without comprehensive insurance coverage.

The timing of the launch intersects with ongoing intellectual property developments. While the core semaglutide patent has expired in India, a secondary patent covering specific formulations remains valid until early 2026, limiting domestic generic competition. Indian courts have recently allowed local firms such as Sun Pharmaceutical Industries and Dr. Reddy's Laboratories to manufacture semaglutide for export to countries where Novo Nordisk holds no patent but have barred domestic sales of these versions until the formulation patent lapses, shaping competitive dynamics in the near term.

Novo Nordisk India's managing director, Vikrant Shrotriya, has acknowledged that the weekly pricing is positioned to balance accessibility with the company's investment in supply infrastructure. He said the goal is to expand reach beyond major urban centres to tier-1 and tier-2 cities and dedicated diabetes clinics, where consistent access to modern therapies has traditionally lagged. Clinicians emphasise that appropriate patient education and specialist referrals will be crucial in ensuring safe and effective use, given that semaglutide therapies require monitoring for gastrointestinal and metabolic effects as part of comprehensive care.

The launch also intersects with broader digital health initiatives. Local health-tech firms are partnering with international drugmakers to offer patient support programmes that provide coaching and adherence tools for individuals on GLP-1 therapies. These services aim to bolster outcomes by integrating medication with lifestyle guidance, reflecting a holistic approach to long-term metabolic health management.